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The endogenous cannabinoid 2-arachidonoyl glycerol (2-AG) is an anti-ﬁbrotic lipid mediator that in-
duces apoptosis in hepatic stellate cells (HSCs), but not in hepatocytes. However, the exact molecular
mechanisms of this selective induction of HSC death are still unresolved. Interestingly, the inducible
isoform of cyclooxygenase, COX-2, can metabolize 2-AG to pro-apoptotic prostaglandin glycerol esters
(PG-GEs). We analyzed the roles of COX-2 and endocannabinoid-derived PG-GEs in the differential
susceptibility of primary activated HSCs and hepatocytes toward 2-AG-induced cell death. HSCs dis-
played signiﬁcant COX-2 expression in contrast to hepatocytes. Similar to 2-AG, treatment of HSCs with
PGD2-GE dose-dependently induced cell death independently from cannabinoid receptors that was
accompanied by PARP- and caspase 3-cleavage. In contrast to 2-AG, PGD2-GE failed to induce signiﬁcant
ROS formation in HSCs, and depletion of membrane cholesterol did not rescue HSCs from PGD2-GE-
induced apoptosis. These ﬁndings indicate differential engagement of initial intracellular signaling
pathways by 2-AG and its COX-2-derived metabolite PGD2-GE, but similar ﬁnal cell death pathways.
Other PG-GEs, such as PGE2-or PGF2a-GE did not induce apoptosis in HSCs. Primary rat hepatocytes were
mainly resistant against 2-AG- and PGD2-GE-induced apoptosis. HSCs, but not hepatocytes were able to
metabolize 2-AG to PGD2-GE. As a proof of principle, HSCs from COX-2/ mice lacked PDG2-GE pro-
duction after 2-AG treatment. Accordingly, COX-2/ HSCs were resistant against 2-AG-induced
apoptosis. In conclusion, the divergent expression of COX-2 in HSCs and hepatocytes contributes to the
different susceptibility of these cell types towards 2-AG-induced cell death due to the generation of pro-
apoptotic PGD2-GE by COX-2 in HSCs. Modulation of COX-2-driven metabolization of 2-AG may provide a
novel physiological concept allowing the speciﬁc targeting of HSCs in liver ﬁbrosis.
© 2016 Elsevier Inc. All rights reserved.1. Introduction
The endocannabinoid system, consisting of arachidonic-acid-
derived lipid mediators, known as endocannabinoids, their spe-
ciﬁc receptors and enzymes for endocannabinoid biosynthesis andedicine I, University of Bonn,
e (S.V. Siegmund).degradation, is critically implicated in the regulation of hepatic
injury and ﬁbrogenesis.
Although the endocannabinoid system is scarcely expressed in
healthy liver, endocannabinoid receptors are upregulated and
endocannabinoid levels increase signiﬁcantly during diseased
states of the organ [1e3]. Cannabinoid receptor 2/mice displayed
increased hepatic ﬁbrogenesis in a model of CCl4-induced liver
ﬁbrosis, whereas CB1/ mice showed reduced ﬁbrogenesis [4,5].
However, the mechanisms by which the endocannabinoid system
regulates liver injury and ﬁbrogenesis are not entirely understood
[3]. Endocannabinoids, such as AEA, 2-AG or N-arachidonoyl
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selectively inducing cell death of activated hepatic stellate cells
(HSCs), the main ﬁbrogenic cell type in the liver, but not in hepa-
tocytes [1e3,6e8]. Hepatocyte cell death is considered to promote
ﬁbrogenesis, whereas elimination of activated HSCs may represent
a mechanism to attenuate hepatic ﬁbrosis [9].
Endocannabinoids evoke a wide spectrum of physiological ac-
tions that are mostly effectuated through the G-protein coupled
cannabinoid receptors CB1 and CB2 [10,11], but can also occur
independently from these receptors [1,2,6,12,13]. Endocannabi-
noids were initially described in the central nervous system, where
they are involved in the control of e.g. food intake, emotions, pain
perception, or sleep [14]. Moreover, endocannabinoids have also
been shown to regulate inﬂammation, cell proliferation, cell death
and lipogenesis in peripheral organs such as the liver [15e19].
We previously demonstrated that 2-AG, the most abundant
endocannabinoid in vertebrate animals, induced reactive oxygen
species (ROS)-triggered, cannabinoid receptor-independent
apoptosis in primary HSCs, but not in hepatocytes due to
different intracellular levels of the antioxidant glutathione and
unequal expression of the endocannabinoid-degrading enzyme
fatty acid amide hydrolase (FAAH) in these cell types [1,8]. How-
ever, these factors alone do not fully explain the remarkable dif-
ference in susceptibility to 2-AG-mediated cell death. Since
activated HSCs express signiﬁcant amounts of the alternative 2-AG-
metabolizing enzyme COX-2 [20] in contrast to hepatocytes [21],
we sought to investigate, whether this discrepancy of COX-2
expression contributes to the differential susceptibility of 2-AG-
induced apoptosis in these two hepatic cell populations.
2. Materials and methods
2.1. Animals and primary cell isolation
Primary HSCs were isolated from livers of balb/c wild-type
(25e35 g, n ¼ 30), C57BL/6J wild-type (25e35 g, n ¼ 4), COX-2/
 (25e35 g, n ¼ 4) mice as previously described [1,8]. COX-2/
mice [22] in a C57BL/6J background were kindly provided by Dr.
Rolf M. Nüsing (Johann Wolfgang Goethe-University, Frankfurt,
Germany). Purity of HSC preparations was 94%, as assessed by
autoﬂuorescence at day 2 after isolation. HSCs were cultured on
uncoated plastic tissue culture dishes as described. HSCs were not
passaged and considered culture-activated between day 7 and 14
after isolation. Primary hepatocytes were isolated from wild-type
balb/c mice (25e35 g, n ¼ 6) and cultured as described previ-
ously [2,7]. All animals received humane care and all procedures
were approved by the local committees for animal studies
(Regierungspr€asidium Karlsruhe and LANUV Recklinghausen).
2.2. Experimental model of liver ﬁbrosis
Liver ﬁbrosis was induced in male balb/c wild-type mice
(30e35 g, n ¼ 4) in a model of cholestatic liver disease by ligating
the common bile duct as described [1,7]. Sham-operated animals
served as controls (n ¼ 4). Seven or 14 days after surgery the mice
were sacriﬁced and the livers were excised for protein and RNA
isolation.
2.3. Cell treatment and detection of cell death
Hepatocytes were kept in serum-free HDM medium for 12 h
before experiments. HSCs were serum-starved with serum-free
DMEM for 12 h. Cells were treated either with 2-AG, prosta-
glandin D2, prostaglandin D2 glycerol ester, prostaglandin E2 glyc-
erol ester, prostaglandin F2a glycerol ester (all Cayman Chemical,Ann Arbor, MI) or vehicle (ethanol; 0.1% ﬁnal concentration), or
actinomycin D (SigmaeAldrich, Deisenhofen, Germany) plus mu-
rine TNFa (R&D Systems, Minneapolis, MN). Where indicated, cells
were pretreated with the CB1 antagonist AM251 (Cayman Chemi-
cal), CB2 antagonist SR144528 (Sanoﬁ-Aventis, Montpellier,
France), pan-caspase inhibitor Z-VAD-FMK (R&D Systems), mem-
brane cholesterol depletor methyl-b-cyclodextrin, or the antioxi-
dant Trolox (both SigmaeAldrich). Cell death wasmeasured by LDH
release into the culture medium according to the manufacturer
(Roche, Mannheim, Germany). Apoptosis was visualized by ﬂuo-
rescent microscopy using an annexin V/propidium iodide-staining
kit (Roche).
2.4. Measurement of prostaglandin glycerol ester levels
The PGD2-GE concentration in lysates of primary mouse hepa-
tocytes and HSCs was measured by a PGD2-MOX EIA kit according
to the manufacturer's instructions (Cayman Chemical).
2.5. Detection of ROS
Reactive oxygen species formation was measured for the indi-
cated time in a multiwell ﬂuorescence plate reader (Fluostar Op-
tima, BMG) with excitation and emission ﬁlters of 485 nm and
535 nm, respectively, using the redox-sensitive dye 5-(and-6)-
chloromethyl-20,70-dichlorodihydroﬂuorescein diacetate (CM-
H2DCFDA; Molecular Probes-Invitrogen, Darmstadt, Germany) as
described [1,8].
2.6. Quantitative RT-PCR analysis
RNA was isolated from serum-starved activated HSCs and he-
patocytes and reverse transcribed as described [1,2,8]. Real time
PCR was performed for 40 cycles of 15 s at 95 C and 60 s at 60 C
using an ABI 7900HT sequence detection system (Applied Bio-
systems, Darmstadt, Germany) as shown [1,2,8], and subsequently
analyzed with the gene expression assay for PTGS2 (Applied Bio-
systems; assay no. Mm00478374_m1).
2.7. Flow cytometric analysis
For intracellular staining of COX-2, cells were ﬁxed with 2%
paraformaldehyde in PBS with 1% FBS/2 mM EDTA at RT. Afterward,
cells were permeabilizedwith 0.5% saponin, followed by incubation
with primary COX-2 antibody (Cayman Chemical) and Alexa647-
coupled secondary antibody on ice. The Fc gamma receptor-
blocking antibody (clone 2.4G2) was added to prevent non-
speciﬁc binding. Acquisition and analysis was conducted using a
Canto II (BD Bioscience, Heidelberg, Germany) and FlowJo software
(Tree Star Inc, Ashland, OR).
2.8. Western blotting
Electrophoresis of protein extracts and subsequent blotting
were performed as described previously [1,8]. Blots were incubated
with anti-COX-2, (Cayman Chemical); anti-caspase-3 or anti-poly-
(ADP-ribose) polymerase (anti-PARP, both Cell Signaling Technol-
ogies, Beverly, MA). Cytochrome c release was determined in S-100
fractions using anti-cytochrome c (BD PharMingen, San Jose, CA) as
described [23]. Blots were reprobed with anti-b-actin antibody
(Cell Signaling Technologies) as loading control.
2.9. Statistical analysis
All data represent the mean of three independent
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cance, unpaired Student's t-tests were performed using SigmaStat
(SPSS, Chicago, IL). P values of 0.05 were considered to be sta-
tistically signiﬁcant.3. Results
3.1. Involvement of COX-2 in 2-AG-induced cell death in HSCs
In parallel to the expression of the HSC activation marker a-SMA
COX-2 mRNA expression increased 54-fold during 14 days in BDL-
treated livers (Fig. 1A, B). Interestingly, protein and mRNA levelsFig. 1. Involvement of COX-2 in 2-AG-induced HSC death. A. aSMA expression was determin
days after bile duct ligation. B. mRNA expression of COX-2 in whole liver was determined
normalization to 18 s (n ¼ 3; *p < 0.05, **<0.001 vs. sham). C. COX-2 protein expression was
expression of COX-2 in primary mouse hepatocytes and HSCs was determined by quantitat
(n ¼ 3; **<0.001 vs. hepatocytes). E. Serum starved primary mouse HSCs were treated with v
death was measured by LDH release into the culture media (**p < 0.001 vs. vehicle). F. Serum
for 12 h. PGD2-GE concentration was measured by PGD2-MOX EIA as described. (n ¼ 3; **p
mouse hepatocytes (black bars), and primary mouse HSCs (gray bars) were treated for 16 h w
was determined by LDH release (n ¼ 3; *p < 0.05, **p < 0.001 vs. vehicle treated HSCs, #pof COX-2 in activated HSCs were 6,8 times higher compared to
hepatocytes (Fig. 1C, D). It was recently shown that 2-AG is ﬁrst
metabolized by COX-2 to unstable PGH2-GE. PGH2-GE acts as a
substrate for PGD-, PGE- or PGF-synthases resulting in PGD2-GE,
PGE2-GE or PGF2a-GE, respectively [24]. To check whether these
potential metabolites of 2-AG were involved in 2-AG-induced cell
death, and to exclude that prostaglandin D2 (PGD2), the COX-2
metabolite of arachidonic acid, may also contribute to 2-AG-
mediated cell death, primary HSCs were exposed to 100 mM of each
substance. Interestingly, only PGD2-GE induced cell death in pri-
mary activated HSCs (Fig. 1E). We were further interested in a
possible differential metabolization of 2-AG to PGD2-GE byed in whole liver extracts by western blotting after sham operation, seven and fourteen
by quantitative real time PCR, shown as a fold induction of sham treated livers after
analyzed in primary mouse hepatocytes and HSCs by western blotting (n ¼ 3). D. mRNA
ive real time PCR, shown as a fold induction of hepatocytes after normalization to 18 s
ehicle () or 100 mM of PGD2, PGF2a-GE, PGE2-GE or PGD2-GE, respectively, for 16 h. Cell
-starved primary hepatocytes and HSCs were treated with vehicle () or 50 mM 2-AG
< 0.001 vs. hepatocytes, ##p < 0.001 vs. untreated HSCs). G. Serum starved primary
ith vehicle (), the indicated concentrations of PGD2-GE or 100 mM of 2-AG. Cell death
< 0.05 vs. vehicle treated hepatocytes).
Fig. 2. Differences or similarities in 2-AG- or PGD2-GE-induced cell death in HSCs. A. Activated primary mouse HSCs were loaded with CM-H2DCFDA (5 mM) for 30 min and treated
with vehicle, 2-AG (100 mM) or PGD2-GE (100 mM). Reactive oxygen species formation was measured in triplicates. The ﬁgure is representative of three independent experiments. B.
After 30 min of pretreatment with either vehicle, Trolox (100 mM) or MCD (1 mM), HSCs were exposed to 2-AG or PGD2-GE (50 mM each) for 16 h. Cell death was analyzed by LDH
assay (*p < 0.05 vs. 2-AG alone). C. HSCs were incubated with the speciﬁc CB1 receptor antagonist AM251 (SR1; 1 mM) or the speciﬁc CB2 receptor antagonist SR144528 (SR2; 1 mM)
30 min before addition of 2- AG or PGD2-GE (50 mM each) for 16 h. Cell death was analyzed by LDH assay. D. HSCs were treated with vehicle, or 50 mM of 2-AG or PGD2-GE,
respectively, for 16 h. Apoptotic cell death is indicated by bright green ﬂuorescence of annexin V (AnnV) and typical morphology, necrotic cell death is shown by red staining of the
nuclei by PI. E. HSCs were treated with 2-AG (left panel, 50 mM) or PGD2-GE (right panel, 50 mM) for the indicated times. Western blotting was performed in cytosolic S-100 fractions
with antibodies directed against cytochrome c and actin. F. HSCs were exposed to PGD2-GE or 2-AG for the indicated times with or without pretreatment of the pan-caspase
inhibitor Z-VAD-FMK (20 mM) for 30 min. Western blotting was performed with antibodies directed against cleaved caspase 3, PARP, and actin. G. HSCs were pretreated with
Z-VAD-FMK (20 mM) for 30 min followed either by incubation with 2-AG or PGD2-GE (50 mM each) for 16 h. Cell death was measured by LDH assay (*p < 0.05 vs. no Z-VAD-FMK
treatment). (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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or vehicle for 16 h (Fig. 1F), no difference in PGD2-GE levels was
observed between vehicle-treated hepatocytes and HSCs as well as
vehicle-treated and 2-AG-stimulated hepatocytes. However, there
was a signiﬁcant induction of PGD2-GE production in 2-AG-stim-
ulated HSCs reaching a 22-fold higher PGD2-GE level compared to
vehicle-treated HSCs and a 15-fold higher PGD2-GE level compared
to 2-AG-treated hepatocytes. When we exposed hepatocytes and
HSCs to increasing concentrations of PGD2-GE, HSCs showed asigniﬁcantly higher susceptibility toward PGD2-GE-induced cell
death than hepatocytes. Hepatocytes underwent cell death only
after exposure to a excessive PGD2-GE concentration of 100 mM, but
not after 2-AG in the same concentration. However, since hepato-
cytes do not signiﬁcantly express COX-2, it is unlikely that intra-
cellular concentrations of PGD2-GE reach substantial cytotoxic
levels in this cell type.
Fig. 3. HSCs from COX-2/ mice are resistant against 2-AG-induced cell death. A. Determination of COX-2 expression levels of wild-type (WT; solid lines) and COX-2/ HSCs
(dashed lines) by ﬂow cytometric analysis. Isotype controls are shaded in gray. B, C. Activated primary HSCs from wild-type (COX-2þ/þ, B) and COX-2/ mice (C) were treated with
50 mM 2-AG for 12 h. PGD2-GE concentration was measured by PGD2 MOX EIA and displayed by fold increase compared to vehicle alone. D. Activated primary HSCs from COX-2þ/þ
and COX-2/ mice were treated with 50 mM 2-AG for 16 h. Cell death was determined by LDH release. (**p < 0.001 vs. vehicle). E. HSCs from COX-2þ/þ and COX-2/ mice were
vehicle treated or treated with 50 mM 2-AG for 16 h. Apoptotic cell death was visualized by green ﬂuorescence of annexin V (AnnV). Necrotic cell death was shown by red staining of
the nuclei by propidium iodide (PI). (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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induced cell death in HSCs
Next we investigated whether PGD2-GE accounts for key fea-
tures of 2-AG-induced HSC cell death. PGD2-GE did not cause sig-
niﬁcant ROS production in HSCs in contrast to 2-AG (Fig. 2A).
Accordingly, antioxidant pretreatment of HSCs by Trolox amelio-
rated 2-AG-, but not PGD2-GE-induced cell death (Fig. 2B). More-
over, in a previous study we demonstrated that 2-AG required
membrane cholesterol interaction in cholesterol-rich lipid rafts to
cause cell death in HSCs [1]. PGD2-GE-induced HSC death on the
contrary could not be blocked by prior membrane cholesterol
depletion by MCD (Fig. 2B). Pretreatment of HSCs with the speciﬁc
CB1 or CB2 receptor antagonists AM251 or SR144528, respectively,
did neither prevent 2-AG- nor PGD2-GE-mediated cell death
(Fig. 2C). These data suggest, that PGD2-GE does not require inter-
action with membrane cholesterol or cannabinoid receptors for
cellular uptake and subsequent induction of cell death in HSCs
since it is produced intracellularly by COX-2 from 2-AG. We next
compared themode of cell death caused by 2-AG and its metabolite
PGD2-GE. As a common ﬁnal pathway, both substances induced
distinct positive Annexin V-staining in HSCs indicating apoptotic
cell death (Fig. 2D). Apoptotic cell death caused by 2-AG as well as
PGD2-GE was preceded by an increase in cytochrome c in S100
fractions starting after 2 h of treatment (Fig. 2E, left and right
panel). Cytochrome c is released from mitochondria undergoingmitochondrial permeability transition and triggers activation of
executioner caspases, such as caspase 3 [23]. Accordingly, HSC
treatment with 25 mM of 2-AG or PGD2-GE, respectively, led to
caspase 3- and PARP-cleavage, two hallmarks of apoptotic cell
death (Fig. 2F). Interestingly, caspase 3 and PARP-cleavage could be
blocked both in 2-AG- and PGD2-GE-mediated apoptosis by the
pan-caspase inhibitor Z-VAD-FMK (Fig. 2F). Moreover, inhibition of
caspase activation by Z-VAD-FMK signiﬁcantly reduced 2-AG- as
well as PGD2-GE-induced HSC apoptosis (Fig. 2G).3.3. Genetic inactivation of COX-2 renders HSCs resistant against 2-
AG-induced cell death
To prove the importance of COX-2 in the mechanisms involved
in 2-AG-mediated cell death in HSCs, we sought to apply HSCs
isolated from COX-2/ mice and to compare these to wild-type
HSCs. First, we conﬁrmed, that activated HSCs isolated from COX-
2 wild-type mice indeed expressed signiﬁcant amounts of COX-2
protein, whereas COX-2/ HSCs lacked the enzyme completely
(Fig. 3A). We then exposed activated wild-type and COX-2/ HSCs
to 2-AG andmeasured the levels of PGD2-GE production (Fig. 3B, C).
In contrast to wild-type HSCs, COX-2/ HSCs did not produce
noticeable amounts of PGD2-GE (Fig. 3C). Thus, COX-2/ HSCs
were resistant against 2-AG-induced cell death in contrast to their
wild-type counterparts (Fig. 3D). We further visualized the
remarkable difference in cell death susceptibility of wild-type and
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4. Discussion
Although liver ﬁbrosis has been regarded as irreversible for a
long time, recent studies in animal models and patients have sug-
gested that hepatic ﬁbrosis is, at least to some degree, a reversible
process [9]. Cell death of activated HSCs as the key ﬁbrogenic cell
population has been linked to the reversal of liver ﬁbrosis. Previ-
ously, we and others demonstrated, that endocannabinoids are able
to selectively induce cell death in activated HSCs, but not in he-
patocytes [1,2,4,6e8] and therefore exhibit antiﬁbrogenic proper-
ties. However, the mechanisms by which endocannabinoids
regulate liver injury and ﬁbrogenesis are not completely under-
stood [3]. Cell death in activated HSCs by endocannabinoids occurs
independently from cannabinoid receptors through interaction
with cholesterol-rich lipid rafts in the cell membrane [1,2,6]. In this
study we show that 2-AG, the most abundant endocannabinoid in
vertebrates, induces a burst of mitochondrial-derived ROS in HSCs,
leading to cytochrome C release and subsequent activation of
effector caspases such as caspase 3, resulting in apoptotic cell
death. Divergence in cell death susceptibility in HSCs and hepato-
cytes are based on differences in the capability to terminate 2-AG-
mediated intracellular events: (i) hepatocytes possess higher levels
of antioxidant glutathione to mitigate ROS production and (ii)
signiﬁcantly express the endocannabinoid-hydrolyzing enzyme
FAAH [1,8]. Thus, the metabolization of endocannabinoids plays a
pivotal role in the control of endocannabinoid signaling. Interest-
ingly, besides the hydrolytic degradation pathways of 2-AG by
FAAH or monoacyl glycerol lipase (MGL), the molecule may also be
metabolized by oxygenases due to their high afﬁnity to the arach-
idonyl moiety of 2-AG. In contrast to AEA, the oxygenase COX-2
speciﬁcally metabolizes 2-AG as efﬁciently as arachidonic acid
[24]. Contrarily, the constitutionally active, non-inducible isoform
COX-1 is not able to metabolize 2-AG [24]. Here we demonstrate
that the expression of COX-2 increased 54-fold during hepatic
ﬁbrogenesis and activated HSCs largely contributed to this increase
of COX-2 expression. Upregulation of COX-2 expression during
ﬁbrogenesis correlates with increased expression of the HSC acti-
vation marker a-SMA (Fig. 1A) and rising hepatic levels of 2-AG [1].
In contrast to hepatocytes, activated HSCswere able to considerably
metabolize 2-AG to PGD2-GE, which represents a biologically
highly active prostaglandin glycerol ester in endocannabinoid
signaling [25]. PGD2-GE appears to be produced intracellularly,
since it did not signal through CB1- or CB2-receptors and, in
contrast to 2-AG, did not interact with membrane cholesterol.
Although PGD2-GE did not generate mitochondrial ROS, it induced
the same ﬁnal death signaling pathway including cytochrome C
release and activation of executioner caspases like its parental
substance 2-AG (see the graphical abstract). The importance of
COX-2 as an endocannabinoid-degrading enzyme has been
demonstrated, if other degradation enzymes, i.e. FAAH or MGL, are
lacking [26]. We have previously shown, that HSCs do not express
FAAH, but MGL [7,8]. However, expression of MGL does not rescue
HSCs from 2-AG-induced cell death [8]. MGL may rather play a role
in terminating PGD2-GE signaling through hydrolyzation [27]. MGL
becomes downregulated in the liver during ﬁbrogenesis in contrast
to COX-2 [8,28], which may in turn contribute to an increase in
PGD2-GE production and thus an increase in 2-AG-induced death of
HSCs. Other inﬂammatory cells in the liver, e.g. Kupffer cells also
express high amounts of COX-2, but also FAAH and MGL (data not
shown) as well as signiﬁcant levels of GSH [29]. Therefore, similar
to hepatocytes, Kupffer cells seem to be protected a priori against 2-
AG-induced cell death.
Finally, the high resistance of COX-2/ HSCs against 2-AG-induced cell death conﬁrms the importance of COX-2 in the dif-
ferential susceptibility of HSCs and hepatocytes towards
endocannabinoid-mediated toxicity.
In conclusion, 2-AG selectively induces cell death in activated
HSCs due to (i) low levels of glutathione, (ii) low expression of
degradation enzymes such as FAAH and (iii) high levels of COX-2,
leading to production of pro-apoptotic PGD2-GE. Consequently,
modulation of COX-2-driven metabolization of 2-AG may provide a
novel physiological concept allowing the speciﬁc targeting of HSCs
in liver ﬁbrosis.
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